We used the median expression value for serum exo-AnxA2 in breast cancer patients (n = 169) to stratify into a high exo-AnxA2 (> 77.87 ng/mL) and a low exo-AnxA2 groups (< 77.87 ng/mL). This evidence concerns the gene ANXA2 and breast carcinoma.